GYNECOLOGY: ENDOCRINOLOGY OF PREGNANCYTrial of SAGE-217 in Patients With Major Depressive DisorderGunduz-Bruce, Handan; Silber, Christopher; Kaul, Inder; Rothschild, Anthony J.; Riesenberg, Robert; Sankoh, Abdul J.; Li, Haihong; Lasser, Robert; Zorumski, Charles F.; Rubinow, David R.; Paul, Steven M.; Jonas, Jeffrey; Doherty, James J.; Kanes, Stephen J.Author Information Sage Therapeutics, Cambridge (H.G.-B., C.S., A.J.S., H.L., R.L., S.M.P., J.J., J.J.D., S.J.K.); Kaul Consulting, Concord (I.K.); University of Massachusetts Medical School and UMass Memorial Healthcare, Worcester (A.J.R.), MA; Atlanta Center for Medical Research, Atlanta, GA (R.R.); Washington University School of Medicine, St. Louis, MO (C.F.Z., S.M.P.); and University of North Carolina School of Medicine, Chapel Hill, NC (D.R.R.) Obstetrical & Gynecological Survey: December 2019 - Volume 74 - Issue 12 - p 723-724 doi: 10.1097/OGX.0000000000000754 Buy Metrics Abstract (Abstracted from N Engl J Med 2019;381(10):903–911) Positive allosteric modification of GABAA receptors via SAGE-217, an oral synthetic neurosteroid, has been proposed as a treatment for major depressive disorder. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.